ANRO (Alto Neuroscience) Other Operating Expense: $-0.00 Mil (TTM As of Mar. 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $26.48
! 2 Warning Signs
View Full Analysis

What is Alto Neuroscience Other Operating Expense?

Alto Neuroscience ANRO -4.20% 12 Other Operating Expense is $-0.00 Mil as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Alto Neuroscience's Other Operating Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00 Mil.

Alto Neuroscience's quarterly Other Operating Expense declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) but then increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.00 Mil).

Alto Neuroscience's annual Other Operating Expense declined from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).

Alto Neuroscience Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience Other Operating Expense Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
-2.97 -1.74 -0.00 -0.00 0.00

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 0.00
ANRO
12GF Score
Alto Neuroscience Inc ANRO
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.00 Mil mean?
Alto Neuroscience (ANRO) has a Other Operating Expense of $-0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Alto Neuroscience and its competitors.
Is Alto Neuroscience's Other Operating Expense too high?
Alto Neuroscience's current Other Operating Expense is $-0.00 Mil. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Other Operating Expense compare to SANA and AVTX?
Alto Neuroscience's Other Operating Expense of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Alto Neuroscience and its competitors. Alto Neuroscience's current Other Operating Expense is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Other Operating Expense of $-0.00 Mil. The current Other Operating Expense is $-0.00 Mil. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Other Operating Expense is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.48
Price